Skip to content
Home > Actiance, Inc. > Risk or Reward? Collaboration and Social Media In the Pharmaceutical Industry
 

Risk or Reward? Collaboration and Social Media In the Pharmaceutical Industry

White Paper Published By: Actiance, Inc.
Actiance, Inc.
Published:  Jan 15, 2015
Type:  White Paper
Length:  16 pages

But what seems like a spoon full of sugar is often a tough pill to swallow when you consider regulatory requirements from agencies like the FDA for use of these networks. Adopting new technologies that allow employees to share information and exchange ideas with each other and with your customers is often the best way to achieve better business results, but doing so can involve considerable risk. Thatís because the content people create using these technologies is subject to the scrutiny of regulators, legislators, and litigators. On top of that, increasing litigation has made it a business requirement to consider solutions that help bring down skyrocketing legal costs. Pharmaceuticals companies must be knowledgeable of, and abide by, specific information retention regulations in every country where they do business, including those countries that prohibit data from leaving the countriesí borders. Not having technology in place to help manage these requirements and increasing risks, or doing so without careful planning, can be a costly mistake.

Read this paper to gain an understanding of: 

  • What the regulatory landscape of the pharmaceuticals industry looks like
  • What concerns you should be aware of from a legal perspective



Tags : 
collaboration, social media risk and reward, retention regulations, data, business requirements

Find Research